Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznan, Poland.
Department of AI R & D, Remidio Innovative Solutions Inc., Glen Allen, Virginia, USA.
Ophthalmic Res. 2023;66(1):1286-1292. doi: 10.1159/000534098. Epub 2023 Sep 27.
INTRODUCTION: Numerous studies have demonstrated the use of artificial intelligence (AI) for early detection of referable diabetic retinopathy (RDR). A direct comparison of these multiple automated diabetic retinopathy (DR) image assessment softwares (ARIAs) is, however, challenging. We retrospectively compared the performance of two modern ARIAs, IDx-DR and Medios AI. METHODS: In this retrospective-comparative study, retinal images with sufficient image quality were run on both ARIAs. They were captured in 811 consecutive patients with diabetes visiting diabetic clinics in Poland. For each patient, four non-mydriatic images, 45° field of view, i.e., two sets of one optic disc and one macula-centered image using Topcon NW400 were captured. Images were manually graded for severity of DR as no DR, any DR (mild non-proliferative diabetic retinopathy [NPDR] or more severe disease), RDR (moderate NPDR or more severe disease and/or clinically significant diabetic macular edema [CSDME]), or sight-threatening DR (severe NPDR or more severe disease and/or CSDME) by certified graders. The ARIA output was compared to manual consensus image grading (reference standard). RESULTS: On 807 patients, based on consensus grading, there was no evidence of DR in 543 patients (67%). Any DR was seen in 264 (33%) patients, of which 174 (22%) were RDR and 41 (5%) were sight-threatening DR. The sensitivity of detecting RDR against reference standard grading was 95% (95% CI: 91, 98%) and the specificity was 80% (95% CI: 77, 83%) for Medios AI. They were 99% (95% CI: 96, 100%) and 68% (95% CI: 64, 72%) for IDx-DR, respectively. CONCLUSION: Both the ARIAs achieved satisfactory accuracy, with few false negatives. Although false-positive results generate additional costs and workload, missed cases raise the most concern whenever automated screening is debated.
简介:许多研究已经证明了人工智能(AI)在可治疗的糖尿病视网膜病变(RDR)早期检测中的应用。然而,直接比较这些多种自动化糖尿病视网膜病变(DR)图像评估软件(ARIAs)具有挑战性。我们回顾性比较了两种现代 ARIA,即 IDx-DR 和 Medios AI 的性能。 方法:在这项回顾性比较研究中,将足够质量的视网膜图像输入两种 ARIA 中进行检测。这些图像来自于在波兰的糖尿病诊所就诊的 811 名连续糖尿病患者。对于每个患者,使用 Topcon NW400 拍摄了 4 张非散瞳图像,45°视野,即两组各有一张视盘和一张黄斑中心图像。使用认证分级器对 DR 的严重程度进行手动分级,结果分为无 DR、任何 DR(轻度非增殖性糖尿病视网膜病变[NPDR]或更严重的疾病)、RDR(中度 NPDR 或更严重的疾病和/或有临床意义的糖尿病性黄斑水肿[CSDME])或威胁视力的 DR(严重 NPDR 或更严重的疾病和/或 CSDME)。将 ARIA 的输出与手动共识图像分级(参考标准)进行比较。 结果:在 807 名患者中,根据共识分级,543 名患者(67%)无 DR。264 名患者(33%)有任何 DR,其中 174 名(22%)为 RDR,41 名(5%)为威胁视力的 DR。Medios AI 检测 RDR 的敏感性为 95%(95%CI:91,98%),特异性为 80%(95%CI:77,83%)。IDx-DR 的敏感性为 99%(95%CI:96,100%),特异性为 68%(95%CI:64,72%)。 结论:两种 ARIA 均达到了令人满意的准确性,假阴性病例很少。虽然假阳性结果会产生额外的成本和工作量,但在讨论自动筛查时,漏诊病例最令人担忧。
BMJ Open Diabetes Res Care. 2020-1
J Ophthalmic Vis Res. 2024-9-16